Search

MannKind Corp

Chiusa

SettoreSettore sanitario

3.29 -3.52

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.23

Massimo

3.41

Metriche Chiave

By Trading Economics

Entrata

-2.4M

-19M

Vendite

19M

109M

P/E

Media del settore

140.5

47.946

EPS

-0.06

Margine di Profitto

-17.401

Dipendenti

591

EBITDA

10M

13M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+121.01% upside

Dividendi

By Acuity

Utili prossimi

4 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

54M

1.2B

Apertura precedente

6.81

Chiusura precedente

3.29

Notizie sul Sentiment di mercato

By Acuity

67%

33%

283 / 340 Classifica in Healthcare

MannKind Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 ott 2026, 20:01 UTC

MannKind Corp shares are declining, continuing a downward trend with notable volatility, hitting a low point around mid-afternoon amid broader market weakness.

8 ott 2026, 20:07 UTC

MannKind Corp shares are declining, retracing from an earlier rally and closing lower compared to Wednesday's close, continuing to trade below its 20-day moving average.

7 ott 2026, 20:00 UTC

News

MannKind shares fell sharply as Truist Securities lowered its price target to $5.00 from $6.00 while maintaining a Buy rating.

6 ott 2026, 19:55 UTC

MannKind Corp shares fell sharply, continuing a decline since Monday's close, despite remaining above its 20-day moving average.

5 ott 2026, 21:01 UTC

MannKind Corp's shares declined during after-market hours on Monday, moving lower after a stable start and contrasting with recent performance above the 20-day moving average.

2 ott 2026, 23:05 UTC

MannKind Corp is trading modestly higher in after-market hours, reflecting typical fluctuations as it remains near the midpoint of its one-month trading range.

1 ott 2026, 21:01 UTC

MannKind Corp is declining in after-market trading, retracing from its opening level and hitting its lowest point shortly after the session began.

30 set 2026, 23:00 UTC

MannKind Corp is trading higher in after-market hours, supported by stronger-than-expected GDP growth and a rise in private sector job additions in September.

29 set 2026, 20:07 UTC

MannKind Corp's shares fell sharply, continuing a downward trend since Monday, and remain significantly below their 20-day moving average.

28 set 2026, 20:41 UTC

MannKind Corp's shares declined in after-market trading, continuing a downward trend since Monday's close and remaining below its 20-day moving average.

25 set 2026, 20:21 UTC

MannKind Corp's shares declined in after-market trading, significantly below its 20-day moving average and near the lower end of its one-month range.

24 set 2026, 20:07 UTC

MannKind Corp's shares fell sharply, continuing a trend with five consecutive lower daily closes and remaining significantly below the 20-day moving average.

23 set 2026, 23:01 UTC

MannKind Corp's shares are trading higher in after-market hours, recovering from earlier losses but remain below their 20-day moving average.

22 set 2026, 23:31 UTC

MannKind Corp is experiencing a notable decline in after-market trading, shifting from a slight gain to a significant loss since Tuesday's close.

21 set 2026, 23:31 UTC

MannKind Corp's shares are advancing in after-market trading, reflecting a notable rise since Monday's close, though still below the 20-day moving average.

18 set 2026, 20:06 UTC

MannKind Corp's shares fell sharply after an early spike, remaining below the 20-day moving average and near the lower end of their one-month range.

17 set 2026, 19:46 UTC

News

MannKind Corp is trading roughly flat as analysts give it an average "Moderate Buy" rating, with seven out of ten firms issuing buy recommendations.

16 set 2026, 23:52 UTC

MannKind Corp is seeing higher after-market trading, reflecting broader market gains despite concerns over TIC outflows and rising Treasury yields.

15 set 2026, 22:02 UTC

MannKind Corp shares are lower in after-market hours, reflecting broader market weakness and concerns from a decline in the NY Empire State Manufacturing Index.

14 set 2026, 19:16 UTC

News

MannKind Corp shares are lower amid mixed analyst ratings and broader market declines, as inflation concerns and supply chain disruptions weigh on sentiment.

11 set 2026, 19:46 UTC

News

MannKind Corp shares are lower today amid broader market trends and inflation data, marking a third consecutive session of declines.

10 set 2026, 22:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting notable gains since Thursday's close, though still below the 20-day moving average.

9 set 2026, 20:01 UTC

Social Media
News

MannKind Corp shares are lower after announcing a licensing deal with Rose Pharma for the development of ROSE-010, an inhaled GLP-1 receptor agonist.

8 set 2026, 20:07 UTC

News

MannKind Corp's shares are higher today amid mixed analyst ratings, including a downgrade from Zacks and a price target increase from Royal Bank of Canada.

4 set 2026, 19:36 UTC

MannKind Corp's shares are advancing, recovering from earlier volatility. The stock is currently above its 20-day moving average amid a stable one-month trading range.

3 set 2026, 23:26 UTC

MannKind Corp shares are higher in after-market trading, reflecting broader market strength amid reduced rate hike expectations. Major indices reported substantial gains.

1 set 2026, 20:08 UTC

MannKind Corp's shares are lower amid a broader market downturn and rising oil prices, which have heightened inflation concerns and interest rate hike expectations.

31 ago 2026, 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

28 ago 2026, 20:07 UTC

MannKind Corp shares are lower today, extending a three-day decline amid rising U.S. Treasury yields and broader equity market concerns.

27 ago 2026, 19:46 UTC

MannKind Corp. shares are trading roughly flat, with no specific news identified. The stock remains around the middle of its one-month trading range.

Confronto tra pari

Modifica del prezzo

MannKind Corp Previsione

Obiettivo di Prezzo

By TipRanks

121.01% in crescita

Previsioni per 12 mesi

Media 7.559 USD  121.01%

Alto 13 USD

Basso 4.16 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MannKind Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

283 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.